USPTO serial 78178639
PROTEOM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHOSID, ROBIN S
- Law office
- TMEG LAW OFFICE 102 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with PROTEOM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Pamela S. Ratliff
JERRY W MILLS BAKER BOTTS LLP2001 ROSS AVE STE 600DALLAS, TX 75201-2900UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemicals for use in the manufacture of pharmaceuticals, cosmetics, and healthcare products; chemicals for use in science, namely, reagents for scientific research; chemicals for use in biotechnology and chemicals produced through biotechnological processes, namely, vaccines, therapeutic proteins and biologics; peptides and polypeptides and small molecules for use in scientific research; all of the aforesaid for use in assays, screens and diagnosis | ACTIVE | — |
| 005 | pharmaceutical preparations for therapeutic, prophylactic and/or pharmacological purposes, namely, for use in relation to abdominal disease,abnormal substrate concentration, asthenia, atrophy, breast disease, cardiovascular disease, degeneration, dermatological disease, dystrophy, ear, nose, throat disease,endocrine disease, fatigue, gastro-intestinal disorder, genetic disorder,genitourinary disease, growth disorder, hematological disease, immune disorder,immunomodulation, infection, inflammation, injury, metabolic disorder, mouth disease, movement disorder, musculoskeletal disease, neoplasm, neurological,mental and cognitive disorder, nutritional disorder, ocular disease, pain,pregnancy disorder, prophylaxis, renal disease, respiratory disease, sleep disorder,somatosensory disorder, temperature disorder, toxicity and intoxication, ulcer,uterine motility; pharmaceutical preparations comprised of peptides and polypeptides for use in relation to abdominal disease, abnormal substrate concentration, asthenia, atrophy, breast disease, cardiovascular disease,degeneration, dermatological disease, dystrophy, ear, nose, throat disease,endocrine disease, fatigue, gastro-intestinal disorder, genetic disorder,genitourinary disease, growth disorder, hematological disease, immune disorder,immunomodulation, infection, inflammation, injury, metabolic disorder, mouth disease, movement disorder, musculoskeletal disease, neoplasm, neurological,mental and cognitive disorder, nutritional disorder, ocular disease, pain,pregnancy disorder, prophylaxis, renal disease, respiratory disease, sleep disorder,comatose disorder, temperature disorder, toxicity and intoxication, ulcer,uterine motility | ACTIVE | — |
| 009 | computer hardware; data processors; computer software for use in the design or identification and characterization of genes and proteins through bioinformatics and related techniques; computer software for the design and identification of chemical entities for drug discovery research; computer software for use in gene therapy and disease diagnosis; computer software comprised of algorithms for use in analysis and data-mining of sequence chemical databases | ACTIVE | — |
| 042 | providing temporary use of online non-downloadable computer software for use in the design or identification and characterization of genes and proteins through bioinformatics and related techniques; providing temporary use of online non-downloadable software for the design or identification of chemical entities for drug discovery research; computer software for use in gene therapy and disease diagnosis; providing temporary use of online non-downloadable computer software comprised of algorithms for use in analysis and data-mining of sequence and chemical databases; providing databases and online databases featuring complementary peptide sequences to all known genes in the human, bacterial,viral, animal and plant genomes; proteomic, genomic, bioinformatics, chemical and scientific consultation services, namely, providing advice and consultation in the fields of genomics, informatics, study of protein properties molecular design;medical, scientific and biotechnological research, namely, identification and characterization of genes and proteins and the design or identification of chemical entities through bioinformatics and related techniques, and providing consultancy and advisory services relating thereto; consultancy, advice and provision of information relating to drug discovery research, disease diagnosis; design,creation and provision of databases, namely, databases for the identification and characterization of genes, proteins and small molecules; design and creation of computer software for data-mining; design, creation and development of proprietary informatics technology, namely for the location and definition of peptide and small molecule ligands; use of bioinformatics and related techniques to design the core regions of molecular functionality and to enable the generation,design, development and validation of peptide and small molecule ligands for existing and novel targets; prediction and design of peptides from DNA sequence data; data-mining operations; scientific research, namely, identification of targets for therapeutic applications and design of chemical inhibitors, agonists and antagonists; design, optimization and development of chemical inhibitors,agonists and antagonists for specific targets for therapeutic applications; design,creation and provision of informatics based programs designed to monitor and research scientific databases and identify potential leads matched to a companydiscovery portfolio; genetic research services, namely, obtaining and analyzing genetic or chemical information; gene sequencing; laboratory research and collaboration with academic research groups in the field of drug discovery and healthcare research; pharmaceutical and biotechnical research, namely,collaboration with pharmaceutical and biotechnology companies; drug discovery and development programs; synthesis of peptides and small molecules | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Proteom Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named PROTEOM
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 1, 2007 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 31, 2007 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 29, 2006 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 29, 2006 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Dec 21, 2005 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 23, 2005 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 22, 2004 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 1, 2004 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 30, 2003 | CFIT | CASE FILE IN TICRS | — |
| Sep 29, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 29, 2003 | PAPER RECEIVED | — | |
| Mar 25, 2003 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2003 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 31, 2002 | PAPER RECEIVED | — |